Any current/future new fundraising through debt or equity?

Currently, there is no immediate plan for debt or equity fundraising. The company has utilized all IPO proceeds that were earmarked for acquisitions. If new mergers and acquisitions (M&A) occur, additional fundraising would be considered. The company is in a healthy cash position with no pressure to raise funds as of the latest quarter. Future fundraising will depend on identifying the right strategic targets for acquisitions. Management is adopting a "wait and watch" approach to evaluate suitable acquisition opportunities before deciding on any new capital raise.

Any current/future capex/capital investment/strategic investment?

The company is utilizing IPO proceeds for working capital and capex, with about INR 40 crores allocated for capex for the rest of the year (Page 9). Maintenance capex expected but no significant new factory or SMT line investments needed soon, as current operations have substantial unused capacity (Page 13). Focus on factory automation and digitalization initiatives expected to be completed by year-end (Page 6). Inorganic expansion strategy is active, aiming to enhance technology capabilities and geographic footprint to better serve customers; discussions and early-stage conversations with pot

Future growth expectations in sales/revenue/volumes?

Long-term growth expectation: 30% CAGR over 5 years, acknowledging some year-to-year volatility. FY ‘26 outlook: Muted revenue growth due to large order completions and geopolitical disruptions, but stronger margin expansion. Higher-quality revenue expected as new orders come with better margins. Current capacity utilization at 55-60%; potential to nearly double revenue by running 3 shifts without major new CAPEX. Order backlog increased with INR 515 crore new orders, half executable within current year, supporting revenue growth. Industrial and Med-tech sectors gaining traction, aided by Alte

Future growth expectations in earnings/operating earnings/profits/EPS?

Cyient DLM aims for a long-term revenue CAGR of around 30% over 5 years, though annual growth may vary due to business dynamics. Margins are expected to improve, with a line of sight to reach early-to-mid teens EBITDA margins sustainably (12%-13%) within 2-3 years. Q1 FY '26 EBITDA margin improved to 9%, with expectations for double-digit margins for the full year driven by better business mix and operating leverage. Operating leverage benefits expected from increased capacity utilization (currently ~55-60%) and control over indirect costs, enabling margin expansion without large capital expen

Current/ Expected Orderbook/ Pending Orders?

Current order backlog stands at approximately INR 2,100-2,138 crores, showing a quarter-on-quarter increase. The backlog is well-balanced with around 40% Aerospace & Defense (A&D), 9% Defense, and the rest split equally between Industrial and Med-Tech segments. Nearly 50% of the recent order intake of INR 515 crores in Q1 is executable within the current financial year. Executability of the order book ranges between 18 to 24 months depending on customer schedules. Book-to-bill ratio reached a high of 1.9 in recent quarters and is expected to remain above 1 throughout FY '26, indicating strong

IN US

Sale is live|00:00:00left today

Cyient DLM LtdQ2 FY25Aerospace & Defense

Cyient DLM Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹462P/E: 45.1Market Cap: ₹3.3K CrSector: Aerospace & Defense

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Long-term growth expectation: 30% CAGR over 5 years, acknowledging some year-to-year volatility.
→FY ‘26 outlook: Muted revenue growth due to large order completions and geopolitical disruptions, but stronger margin expansion.
→Higher-quality revenue expected as new orders come with better margins.
→Current capacity utilization at 55-60%; potential to nearly double revenue by running 3 shifts without major new CAPEX.
→Order backlog increased with INR 515 crore new orders, half executable within current year, supporting revenue growth.
→Industrial and Med-tech sectors gaining traction, aided by Altek acquisition, contributing to consistent and less volatile order inflows.
→Domestic market shows higher growth potential than exports; already building a solid foundation domestically.
→Book-to-bill ratio expected above 1 throughout the year, indicating sustained order intake growth.
→B2S (build-to-spec) revenue contribution expected to grow gradually, reaching ~5% in FY ‘26.
→Growth supported by ongoing sales team strengthening and digitalization/automation initiatives.

Margin guidance

Category 1

→Cyient DLM aims for a long-term revenue CAGR of around 30% over 5 years, though annual growth may vary due to business dynamics.
→Margins are expected to improve, with a line of sight to reach early-to-mid teens EBITDA margins sustainably (12%-13%) within 2-3 years.
→Q1 FY '26 EBITDA margin improved to 9%, with expectations for double-digit margins for the full year driven by better business mix and operating leverage.
→Operating leverage benefits expected from increased capacity utilization (currently ~55-60%) and control over indirect costs, enabling margin expansion without large capital expenditure.
→Profit After Tax (PAT) growth expected to improve with higher margins and stable costs.
→Enhanced sales efforts and higher-margin order backlog contribute to confident margin improvement and profit growth trajectory.
→Short term profit/margin impacted by noncash amortization and geopolitical supply chain disruptions but expected to normalize over the year.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, there is no immediate plan for debt or equity fundraising.
→The company has utilized all IPO proceeds that were earmarked for acquisitions.
→If new mergers and acquisitions (M&A) occur, additional fundraising would be considered.
→The company is in a healthy cash position with no pressure to raise funds as of the latest quarter.
→Future fundraising will depend on identifying the right strategic targets for acquisitions.
→Management is adopting a "wait and watch" approach to evaluate suitable acquisition opportunities before deciding on any new capital raise.

Order book

Yes

→Current order backlog stands at approximately INR 2,100-2,138 crores, showing a quarter-on-quarter increase.
→The backlog is well-balanced with around 40% Aerospace & Defense (A&D), 9% Defense, and the rest split equally between Industrial and Med-Tech segments.
→Nearly 50% of the recent order intake of INR 515 crores in Q1 is executable within the current financial year.
→Executability of the order book ranges between 18 to 24 months depending on customer schedules.
→Book-to-bill ratio reached a high of 1.9 in recent quarters and is expected to remain above 1 throughout FY '26, indicating strong order inflow relative to billing.
→The order intake has become more consistent and less volatile post-acquisition of Altek and with a pivot towards Industrial and Med-Tech segments.
→The company is confident of sustaining the momentum in order intake and improving margin profiles going forward.

Capex plans

Yes

→The company is utilizing IPO proceeds for working capital and capex, with about INR 40 crores allocated for capex for the rest of the year (Page 9).
→Maintenance capex expected but no significant new factory or SMT line investments needed soon, as current operations have substantial unused capacity (Page 13).
→Focus on factory automation and digitalization initiatives expected to be completed by year-end (Page 6).
→Inorganic expansion strategy is active, aiming to enhance technology capabilities and geographic footprint to better serve customers; discussions and early-stage conversations with potential acquisition targets ongoing (Pages 6, 10, 11).
→No current plans for immediate large capital investments beyond working capital and maintenance capex, but open to sizable acquisitions if strategically aligned (Pages 10, 15).

How does Cyient DLM Ltd rank vs peers in Aerospace & Defense?

Pro feature

1Cyient DLM Ltd

Rev 3Mar 1

See full Aerospace & Defense sector rankings

Want more stocks like Cyient DLM Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio